Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 11:9:862382.
doi: 10.3389/fcvm.2022.862382. eCollection 2022.

Progression of Mitral Regurgitation in Rheumatic Valve Disease: Role of Left Atrial Remodeling

Affiliations

Progression of Mitral Regurgitation in Rheumatic Valve Disease: Role of Left Atrial Remodeling

Nayana F A Gomes et al. Front Cardiovasc Med. .

Abstract

Introduction: Mitral regurgitation (MR) is the most common valve abnormality in rheumatic heart disease (RHD) often associated with stenosis. Although the mechanism by which MR develops in RHD is primary, longstanding volume overload with left atrial (LA) remodeling may trigger the development of secondary MR, which can impact on the overall progression of MR. This study is aimed to assess the incidence and predictors of MR progression in patients with RHD.

Methods: Consecutive RHD patients with non-severe MR associated with any degree of mitral stenosis were selected. The primary endpoint was a progression of MR, which was defined as an increase of one grade in MR severity from baseline to the last follow-up echocardiogram. The risk of MR progression was estimated accounting for competing risks.

Results: The study included 539 patients, age of 46.2 ± 12 years and 83% were women. At a mean follow-up time of 4.2 years (interquartile range [IQR]: 1.2-6.9 years), 54 patients (10%) displayed MR progression with an overall incidence of 2.4 per 100 patient-years. Predictors of MR progression by the Cox model were age (adjusted hazard ratio [HR] 1.541, 95% CI 1.222-1.944), and LA volume (HR 1.137, 95% CI 1.054-1.226). By considering competing risk analysis, the direction of the association was similar for the rate (Cox model) and incidence (Fine-Gray model) of MR progression. In the model with LA volume, atrial fibrillation (AF) was no longer a predictor of MR progression. In the subgroup of patients in sinus rhythm, 59 had an onset of AF during follow-up, which was associated with progression of MR (HR 2.682; 95% CI 1.133-6.350).

Conclusions: In RHD patients with a full spectrum of MR severity, progression of MR occurs over time is predicted by age and LA volume. LA enlargement may play a role in the link between primary MR and secondary MR in patients with RHD.

Keywords: atrial fibrillation; left atrial; mitral regurgitation; mitral stenosis; progression; rheumatic heart disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Study population.
Figure 2
Figure 2
Long-term follow-up of patients with rheumatic heart disease (RHD).
Figure 3
Figure 3
Multivariable predictive models for prediction of mitral regurgitation (MR) progression in patients with rheumatic heart disease (RHD). Cox proportional hazards model considering mitral regurgitation (MR) progression as the primary event and the Fine-Gray model analyzing death and mitral valve replacement as a competing event.
Figure 4
Figure 4
Incidence of mitral regurgitation (MR) progression according to cardiac rhythm. Patients who had sinus rhythm at baseline but with a new-onset of atrial fibrillation during the follow-up were at risk for progression with a hazard ratio of 2.447 (95% CI 1.035–5.788). Patients with permanent atrial fibrillation were at the highest risk for progression with a hazard ratio of 4.459 (95% CI 2.148–9.631) when compared with patients in sinus rhythm.

References

    1. Watkins DA, Johnson CO, Colquhoun SM, Karthikeyan G, Beaton A, Bukhman G, et al. . Global, regional, and national burden of rheumatic heart disease, 1990-2015. N Engl J Med. (2017) 377:713–22. 10.1056/NEJMoa1603693 - DOI - PubMed
    1. Watkins DA, Beaton AZ, Carapetis JR, Karthikeyan G, Mayosi BM, Wyber R, et al. . Rheumatic heart disease worldwide: JACC scientific expert panel. J Am Coll Cardiol. (2018) 72:1397–416. 10.1016/j.jacc.2018.06.063 - DOI - PubMed
    1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. . Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. (2020) 76:2982–3021. - PMC - PubMed
    1. Saxena A. Echocardiographic diagnosis of chronic rheumatic valvular lesions. Glob Heart. (2013) 8:203–12. 10.1016/j.gheart.2013.08.007 - DOI - PubMed
    1. Nunes MCP, Sable C, Nascimento BR, Lima EM, da Silva JLP, Diamantino AC, et al. . Simplified echocardiography screening criteria for diagnosing and predicting progression of latent rheumatic heart disease. Circ Cardiovasc Imaging. (2019) 12:e007928. 10.1161/CIRCIMAGING.118.007928 - DOI - PubMed

LinkOut - more resources